



IAW

PATENT
Attorney Docket No.: CIT1360-3

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Duncan Odom Art Unit: 1645
Application No.: 10/672,408 Examiner: A.M. Navarro
Filed: September 26, 2003 Confirmation No.: 1838
Title: CHIMERIC CELL-TARGETING PATHOGENIC ORGANISM AND
METHOD OF THERAPEUTIC USE


MAIL STOP AMENDMENT
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

TRANSMITTAL LETTER

Sir:

Transmitted herewith for the above-identified application please find:

1. Information Disclosure Statement (2 pgs.);
2. Form PTO-1449 (1 pg. in duplicate);
3. International Search Report (3 pgs.);
4. Two (2) References and
5. Return Receipt Postcard.

CERTIFICATION UNDER 37 CFR §1.8	
I hereby certify that the documents referred to as enclosed herein are being deposited with the United States Postal Service with sufficient postage as first class mail on this date, July 26, 2004, in an envelope addressed to: MAIL STOP AMENDMENT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.	
Gregory P. Austin (Name of Person Mailing Paper)	
 (Signature)	July 26, 2004 (Date)

In re Application of:
Duncan Odom
Application No.: 10/672,408
Filed: September 26, 2003
Page 2

PATENT
Attorney Docket No.: CIT1360-3

No fee is deemed necessary in connection with the filing of this Information Disclosure Statement, because it is being filed prior to the mailing of a first office action on the merits of the above-identified application. However, if any fee is required, authorization is hereby given to charge the amount of any such fee, or credit any overpayment, to Deposit Account No. 50-1355. A duplicate copy of this transmittal letter is enclosed.

Respectfully submitted,

Date: July 26, 2004



Lisa A. Haile, J.D., Ph.D.
Registration No. 38,347
Telephone: (858) 677-1456
Facsimile: (858) 677-1465

GRAY CARY WARE & FREIDENRICH LLP
4365 Executive Drive, Suite 1100
San Diego, California 92121-2133
USPTO CUSTOMER NO. 28213



PATENT
Attorney Docket No.: CIT1360-3

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Duncan Odom
Application No.: 10/672,408
Filed: September 26, 2003
Title: CHIMERIC CELL-TARGETING PATHOGENIC ORGANISM AND
METHOD OF THERAPEUTIC USE

Art Unit: 1645
Examiner: A.M. Navarro
Confirmation No.: 1838


MAIL STOP AMENDMENT
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

In accordance with 37 C.F.R. § 1.97, Applicant brings to the Examiner's attention the parent application, U.S. Serial No. 10/002,389, filed November 30, 2001, now Patent No. 6,638,756, which is relied upon for an earlier filing date under 35 U.S.C. § 120.

Applicant respectfully requests that the references supplied in compliance with 37 C.F.R. § 1.97 in the above-referenced parent application, as well as those cited during its examination, be made of record. Copies of the documents will be found in the above-referenced parent application. For the convenience of the Examiner, the references are listed on the attached Form PTO-1449. Two additional references also are listed on the attached Form PTO-1449 and copies of those references are enclosed herewith. The International Search Report issued for the counterpart International application also is enclosed herewith.

CERTIFICATION UNDER 37 CFR §1.8	
I hereby certify that the documents referred to as enclosed herein are being deposited with the United States Postal Service with sufficient postage as first class mail on this date, July 26, 2004, in an envelope addressed to: MAIL STOP AMENDMENT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.	
Gregory P. Austin (Name of Person Mailing Paper)	
 (Signature)	July 26, 2004 (Date)


In re Application of:
Duncan Odom
Application No.: 10/672,408
Filed: September 26, 2003
Page 2

PATENT
Attorney Docket No.: CIT1360-3

No fee is deemed necessary in connection with the filing of this Information Disclosure Statement, because it is being filed prior to the mailing of a first office action on the merits of the above-identified application. However, if any fee is required, authorization is hereby given to charge the amount of any such fee, or credit any overpayment, to Deposit Account No. 50-1355.


Respectfully submitted,

Date: July 26, 2004



Lisa A. Haile, J.D., Ph.D.
Registration No. 38,347
Telephone: (858) 677-1456
Facsimile: (858) 677-1465

GRAY CARY WARE & FREIDENRICH LLP
4365 Executive Drive, Suite 1100
San Diego, California 92121-2133
USPTO CUSTOMER NO. 28213

FORM PTO-1449 U.S. Department of Commerce Patent and Trademark Office 	Docket No.: CIT1360-3	Application No.: 10/672,408
	Applicants: Duncan Odom	Confirmation No.: 1838
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Filing Date: September 26, 2003	Group Art Unit: 1645

U.S. PATENT DOCUMENTS

EXAM. INITIALS		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA	6,083,751 A	07/04/2000	Feldhaus et al.	435	372.3	05/09/1996
	AB	6,346,411 B1	02/12/2002	Hostetter et al.	435	254.11	03/08/1999

FOREIGN PATENT DOCUMENTS

EXAM. INITIALS		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages)

	AC	Calderone et al., "Adherence and Receptor Relationships of <i>Candida albicans</i> ", <i>Microbiol. Rev.</i> , 55(1):1-20 (1991)
	AD	Gale et al., "Linkage of Adhesion, Filamentous Growth, and Virulence in <i>Candida albicans</i> to a Single Gene, <i>INT1</i> ," <i>Science</i> , 279:1355-1358 (1998)
	AE	Moritz et al., "Cytotoxic T lymphocytes with a grafted recognition specificity for ERBB2-expressing tumor cells," <i>Proc. Natl. Acad. Sci. USA</i> , 91:4318-4322 (1994)
	AF	Wels et al., "Biotechnological and gene therapeutic strategies in cancer treatment," <i>Gene</i> 159:73-80 (1995)
	AG	Sonneborn et al., "Control of White-Opaque Phenotypic Switching in <i>Candida albicans</i> by the Efg1p Morphogenetic Regulator", <i>Infect. Immun.</i> , 67(9):4655-4660 (1999)

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form 1449